Michael Lahn

Trials

Studies that name Michael Lahn as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:17 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT06887803 · A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

  iOnctura · recruiting · Myelofibrosis (MF) · study director
• Ph1/Ph2
  NCT06879717 · A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

  iOnctura · active not recruiting · Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC · study director
• Ph2
  NCT06717126 · A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

  iOnctura · active not recruiting · Uveal Melanoma, Ocular Melanoma · study director
• Ph1
  NCT04328844 · A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

  iOnctura · active not recruiting · Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC · study director

Grants

NIH projects from RePORTER, fetched 2026-11-11 19:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.